People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Zavante Therapeutics, Inc. | — | Pharmaceuticals | Series C | $60.2M | $1.6B | 2016 |
Kevin L. Finney at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin L. Finney on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Cam L. Garner | 1 | 11 |
| Theodore R. Schroeder | 1 | 4 |
| Cam L. Gallagher | 1 | 2 |
| Cam R. Gallagher | 1 | 2 |
| Cam R. Garner | 1 | 1 |
| Patrick L. Heron | 1 | 1 |
| David L. Hirsch | 1 | 1 |
| Evelyn J. Ellis-Grosse | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.